People paying out of pocket for Ozempic or Wegovy may soon see lower costs, as Novo Nordisk rolls out new price discounts for its popular GLP-1 medications.

Novo Nordisk (NVO) is cutting prices to challenge rival Eli Lilly (LLY) in the obesity-drug market, signaling a more aggressive push to regain U.S. market share. “Wegovy (semaglutide) injection 0.25 ...

Eli Lilly (LLY) is cutting prices for starting doses of Zepbound single-dose vials on its LillyDirect direct-to-consumer ...

Low-dose semaglutide (Ozempic, Wegovy) improved glycemic control and weight outcomes in a randomized trial of adults whose ...

Novo Nordisk's new discount offer is set to run until the end of March, allowing individuals with a preion to purchase the lowest doses of Ozempic and Wegovy for only $199 per month for the first two ...

Eli Lilly reduced Zepbound vial prices for self-paying patients via LillyDirect, aiming to lower obesity treatment costs and ...

Insulin resistance is a growing health concern worldwide, linked to a variety of conditions such as type 2 diabetes, polycystic ovary syndrome (PCOS), Alzheimer's disease, metabolic syndrome, and ...

What used to be a whisper: “I’m on Ozempic” has recently become a shout. Celebrities like Serena Williams, Oprah, and Kelly Clarkson are on the jab, AKA an injectionable medication like Ozempic, ...